Thus, therapies targeting Type 2 signaling, such as monoclonal antibodies directed against IL-13, IL-5, IL-33, TSLP (thymic stromal lymphopoietin) or their receptors, or against IgE, have been effective in treating allergic asthma without inducing a substantial cost in parasite clearance (Hammad and Lambrecht, 2021). This evidence concerns the gene IL13 and allergic asthma.